Creative Biolabs provides small molecule PK studies and tissue distribution service, quantifying ADME profiles and organ-specific accumulation. We utilize LC-MS/MS and radiolabeling to evaluate bioavailability and metabolic stability for preclinical lead optimization.
Learn More →Small Molecule DMPK Evaluation Services
Creative Biolabs bridges the gap between in vitro potency and in vivo exposure by providing a comprehensive analytical framework for a compound's metabolic fate. By evaluating systemic exposure, tissue distribution, and clearance pathways early in the design-make-test-analyze (DMTA) cycle, we prioritize structural classes with optimal drug-like properties. Our experts balance target affinity with structure-property relationships (SPR), identifying metabolic "soft spots" or permeability barriers to de-risk pipelines for traditional inhibitors and novel bifunctional degraders before they reach costly development stages.
Background Featured Services Workflow Publication Why Choose Us FAQs Customer Review Related Services Contact Us
Strategic Mechanistic Perspectives in Small Molecule DMPK
Small molecule drug metabolism and pharmacokinetics (DMPK) represents the vital quantitative bridge between chemical design and biological outcomes, describing how a compound is absorbed, distributed, metabolized, and eliminated by the body. Modern industry data indicate that nearly half of all project terminations during the lead optimization phase result from inadequate ADME properties rather than a lack of biological target affinity. At Creative Biolabs, we go beyond simple data reporting to provide deep mechanistic explanations for molecular behavior. By utilizing a rigorous SPR approach, we empower researchers to navigate the delicate balance between enhancing metabolic stability and maintaining target potency.
Comprehensive Portfolio of Small Molecule DMPK Solutions
At Creative Biolabs, we provide a full spectrum of DMPK services tailored to meet the specific requirements of early-stage lead generation and advanced preclinical optimization. Our offerings are structured to provide high-resolution data across all ADME dimensions, ensuring a clear path toward candidate selection.
Small Molecule PK Studies & Tissue Distribution
Small Molecule LC-MS/MS Bioanalysis Method Development
Creative Biolabs provides small molecule LC-MS/MS bioanalysis method development, specializing in high-sensitivity quantification and matrix effect mitigation. We deliver validated assays for PK/PD studies and regulated bioanalysis to accelerate preclinical development.
Learn More →Small Molecule Metabolite Profiling & Excretion Route
Creative Biolabs provides small molecule metabolite profiling and excretion route services, quantifying biotransformation pathways and clearance mechanisms. We utilize mass spectrometry to identify metabolic stability and ensure regulatory compliance.
Learn More →Consult with Our DMPK Specialists to Decode Your Compound's Metabolic Fate
Workflow
Our structured approach ensures that every project receives the scientific rigor it deserves, moving systematically from initial characterization to comprehensive in vivo analysis.
Publication
This review summarizes the DMPK of antisense oligonucleotide (ASO) therapeutics, highlighting their typical absorption, distribution, metabolism, excretion, and drug-drug interaction profiles compared with small molecules. Unlike small drugs, ASOs share similar DMPK characteristics within each chemistry type (e.g., PS-ASOs, PMOs), with distinct mechanisms of tissue distribution (receptor-mediated endocytosis) and metabolism (nuclease degradation). The authors discuss bioanalytical challenges, radiolabeling, in vitro models, and delivery approaches, providing practical points for optimizing ASO DMPK evaluation.
Fig.1 Schematic depicting the cellular uptake and intracellular trafficking pathways of ASO. 1
Why Choose Us?
Choosing Creative Biolabs for your DMPK evaluation ensures access to a sophisticated intersection of medicinal chemistry expertise and ultra-sensitive bioanalytical technology. Our platform stands out through the seamless integration of predictive AI modeling, which allows us to prioritize structural analogs in silico before moving to high-cost wet-lab assays, significantly reducing overall research and development expenditure. We offer unmatched species versatility, supporting validated models across rodents, canines, and non-human primates to provide the cross-species data essential for accurate human PK projections. Furthermore, our state-of-the-art LC-MS/MS instrumentation provides the high dynamic range and sensitivity required to quantify difficult-to-detect modalities even at micro-dose concentrations.
Leverage Our Advanced Bioanalytical Platform—Inquire for a Custom Quote
FAQs
What is the minimum compound requirement for an initial IV/PO PK study?
Typically, 5-10 mg of high-purity compound is sufficient for a standard rodent study. However, for specialized tissue distribution or larger species, we recommend contacting our team for a precise requirement based on your dosing target.
How do you address poor aqueous solubility during PK testing?
Our formulation team screens various vehicles (e.g., pH adjustment, co-solvents, or complexation with cyclodextrins) to ensure optimal and consistent exposure, which is essential for accurate PK parameter calculation.
Can you identify reactive metabolites that might cause toxicity?
Yes. Our metabolite identification service uses high-resolution mass spectrometry to detect glutathione adducts and other indicators of reactive species, allowing you to design out these liabilities early.
Customer Review
-
Superior Bioanalytical Sensitivity
Utilizing Creative Biolabs' DMPK services has significantly facilitated our understanding of low-exposure molecules. Their ability to distinguish parent compounds from complex metabolites in the brain matrix was pivotal for our program. - Dr. Ar** S -
Robust Discovery Data
The clarity of the metabolic stability reports and the precision of the free fraction calculations provided the necessary evidence to justify our dosing frequency during our latest review. - Dr. L** K
Related Services
In Vitro ADME Screening Service
Creative Biolabs provides comprehensive in vitro ADME screening, quantifying solubility, permeability, and metabolic stability. We evaluate protein binding and transporter interactions to predict human PK parameters and accelerate biologic lead optimization.
Learn More →Cellular Stress Assessment Service
Creative Biolabs provides cellular stress assessment services, quantifying HSP27 biomarkers and biochemical parameters. We evaluate oxidative, chemical, and heat stress responses in cell models to predict drug-induced toxicity and ADME safety.
Learn More →How to Contact Creative Biolabs
Creative Biolabs offers a world-class platform for small molecule DMPK evaluation, combining advanced bioanalytics with strategic medicinal chemistry insights. From Tier 1 in vitro screening to complex in vivo PK/PD modeling, we provide the actionable data you need to progress your program faster and safer. Our focus on precision and scientific readiness makes us the preferred partner for biopharmaceutical innovators worldwide.
Contact our scientific team today to discuss your project requirements and request a customized quote.
Reference
- Takakusa, H., et al. "Drug Metabolism and Pharmacokinetics of Antisense Oligonucleotide Therapeutics: Typical Profiles, Evaluation Approaches, and Points to Consider Compared with Small Molecule Drugs." Nucleic Acid Ther 33.2 (2023): 83-94. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.1089/nat.2022.0054
Download our brochureLoading case studies...
Online Inquiry